AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 4)
Description: Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
Study NCT00872599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fenofibrate
Description: Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
Study NCT00872599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
Study NCT03112265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems
Description: MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
Study NCT03112265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring and Feedback System
Description: For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
Study NCT03112265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
Study NCT02093572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 standard meals/day
Study NCT02093572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 meals/day (omit breakfast)
Study NCT01288534 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
Study NCT01271725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 weekly
Description: Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
Study NCT01271725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40mg once daily (OD)
Description: Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
Study NCT01271725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m2 weekly
Description: Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
Study NCT05482828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JGT (Jaeumgeonbi-Tang) tablet
Description: JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
Study NCT05482828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
Study NCT04230915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative nerve monitoring
Description: This group will determine as those who were administered 0.3 mg/kg rocuronium,
Study NCT03488966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Eating and Awareness Training
Description: Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
Study NCT03571126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)
Study NCT03571126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
Study NCT03854838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolipalimab
Description: Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
Study NCT03854838 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reirradiation
Description: intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
Study NCT02618265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile terminal
Description: multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
Study NCT02618265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional management
Description: aspirin or clopidogrel monotherapy or double treatment for
Study NCT02618265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: website platform management
Description: second prevention based on website platform management
Study NCT04115800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Sirolimus
Description: Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
Study NCT01560286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 165 (rAvPAL-PEG)
Description: Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
Study NCT04377217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video recording
Description: The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
Study NCT04303481 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: normal diet
Description: Control
Study NCT04303481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight loss program kit
Description: Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.
Study NCT04303481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight loss program kit with A. muciniphila prebiotics
Description: Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABPM
Description: Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABPM
Description: Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The arterial stiffness and endothelial reactivity
Description: The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The arterial stiffness and endothelial reactivity
Description: The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Euroqol EQ-5D-5L
Description: Answer Euroqol EQ-5D-5L at baseline and at the end of the study
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Euroqol EQ-5D-5L
Description: Answer Euroqol EQ-5D-5L at baseline and at the end of the study
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lectures about knee OA
Description: Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lectures about knee OA
Description: Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous intensity exercise
Description: 40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
Study NCT04052308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises with varying intensity and interval
Description: 40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
Study NCT04373226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnitude comparison tasks and neuropsychological testing
Description: neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
Study NCT04373226 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Magnitude comparison tasks and neuropsychological testing
Description: neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
Study NCT02324283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.
Study NCT02324283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
Study NCT01340586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 5 mg, Once, 4 days
Study NCT01340586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 5 mg, Twice, 15 days
Study NCT03053947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Ketamine
Description: Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
Study NCT01172626 — intervention group
Intervention type: DRUG
Intervention: valproate sodium
Description: oral administration,15-30mg/kg,daily
Study NCT01172626 — intervention group
Intervention type: GENETIC
Intervention: Polymorphism Analysis
Description: Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
Study NCT01172626 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
Study NCT03385148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Sgc8
Description: underwent a standard routine 18F-FDG PET/CT first, and then injected 10\~20 MBq 68Ga-Sgc8
Study NCT02432586 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive Education
Description: Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart insulin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart insulin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT03824002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study NCT02588235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe and Atorvastatin
Description: atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
Study NCT02588235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin (20 mg/day）
Study NCT05089643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
Study NCT05089643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
Study NCT01051687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit.
Study NCT01980095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-105
Description: The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days.
Study NCT01980095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
Study NCT03685630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Solution for injection~* Concentration: 10 mg/ml~* Route of administration: Intravenous injection
Study NCT03502525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Break the Cycle Intervention
Description: The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
Study NCT02046707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: initial evaluation
Study NCT02046707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Period of cardiac rehabilitation
Study NCT00755248 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Grafting
Description: Coronary Artery Bypass Grafting on- or off-pump
Study NCT02046707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: final evaluation
Study NCT02046707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Concentric and eccentric exercise sessions
Study NCT02092285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 50mg or 100mg solution for injection; subcutaneous injection
Study NCT04127695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-0805
Description: ABBV-0805 administered by IV infusion.
Study NCT02225093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Oral
Study NCT02225093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Oral /.L
Study NCT02225093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT02225093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Placebo to Match (PTM)
Description: Oral
Study NCT00774293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
Study NCT00774293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arnica and Bryonia
Description: Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
Study NCT02114138 — intervention group
Intervention type: PROCEDURE
Intervention: pathogenesis of perioperative acute kidney injury
Description: understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
Study NCT02114138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine collection
Description: urine collection will be performed on both the control group and hospitalized participants
Study NCT01699230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis